These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 27761727)
1. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının. Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727 [TBL] [Abstract][Full Text] [Related]
2. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma. Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L Tumori; 2014; 100(5):559-67. PubMed ID: 25343553 [TBL] [Abstract][Full Text] [Related]
3. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552 [TBL] [Abstract][Full Text] [Related]
4. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712 [TBL] [Abstract][Full Text] [Related]
5. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Attanoos RL; Gibbs AR Histopathology; 2003 Nov; 43(5):444-52. PubMed ID: 14636270 [TBL] [Abstract][Full Text] [Related]
6. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma. Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868 [TBL] [Abstract][Full Text] [Related]
7. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983 [TBL] [Abstract][Full Text] [Related]
8. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Pan CC; Chen PC; Chou TY; Chiang H Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817 [TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. Klebe S; Swalling A; Jonavicius L; Henderson DW J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863 [TBL] [Abstract][Full Text] [Related]
10. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Brown RW; Clark GM; Tandon AK; Allred DC Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019 [TBL] [Abstract][Full Text] [Related]
11. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651 [TBL] [Abstract][Full Text] [Related]
12. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439 [TBL] [Abstract][Full Text] [Related]
13. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Miettinen M; Sarlomo-Rikala M Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644 [TBL] [Abstract][Full Text] [Related]
16. Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma. Saito R; Kasajima A; Taniuchi S; Fujishima F; Ishida K; Nakamura Y; Yamanda S; Takahashi T; Hitomi H; Murakami K; Watanabe M; Sasano H Pathol Int; 2012 Oct; 62(10):709-15. PubMed ID: 23005599 [TBL] [Abstract][Full Text] [Related]
17. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Dejmek A Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821 [TBL] [Abstract][Full Text] [Related]
18. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura. Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195 [TBL] [Abstract][Full Text] [Related]
19. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Gotzos V; Vogt P; Celio MR Pathol Res Pract; 1996 Feb; 192(2):137-47. PubMed ID: 8692714 [TBL] [Abstract][Full Text] [Related]
20. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Leers MP; Aarts MM; Theunissen PH Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]